Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLOPEC: Adjuvant HIPEC in Colon Cancer
NCT02231086Phase 3Completed
- Sponsor
- University of Amsterdam
- Start
- Mar 2015
- Primary completion
- Sep 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colon cancer (2 arms), sponsored by University of Amsterdam. Primary endpoint: Peritoneal Recurrence Free Survival at 18 Months. Started Mar 2015; status: completed.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02231086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231086.